Alnylam's rare genetic disorder drug gets early U.S. approval

Alnylam's rare genetic disorder drug gets early U.S. approval

By, Admin 21 November 2019

Alnylam Pharmaceuticals Inc on Wednesday received an early U.S. approval for its gene silencing drug to treat patients with a rare genetic disorder that can cause severe pain. The drug, Givlaari, uses a mechanism known as RNA interference to target and "silence" specific genetic material, blocking the production of the protein that causes the disease called acute hepatic porphyria. The buildup of the protein can cause acute seizures that occur suddenly and can produce permanent neurological damage and death, according to the U.S. Food and Drug Administration. Alnylam did not immediately respond to a Reuters request for pricing details. Shares of the company were up 7.5% before trading was halted ahead of the announcement. "Givlaari will be an entirely new therapy for a poorly treated rare disease patient population," said Oppenheimer analyst Leland Gershell, adding he expected peak sales of $560 million.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!